Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Novo Nordisk's next-gen drug CagriSema beat Eli Lilly's tirzepatide in a late-stage diabetes trial, delivering 12.4% average weight loss vs. Lilly's 9.1%. The weekly injection combines cagrilintide and semaglutide and also matched Lilly's drug on blood sugar control. This is a notable rebound for Novo after CagriSema fell short of Lilly's Zepbound in an earlier head-to-head obesity trial.
Novo Nordisk's experimental next-generation drug, CagriSema, has outperformed Eli Lilly's tirzepatide in a late-stage clinical trial involving patients with diabetes. The weekly injectable combines cagrilintide — a molecule that mimics the pancreatic hormone amylin — with semaglutide, the active ingredient in Novo's blockbuster weight-loss drug Wegovy. The trial compared a 1 mg dose of CagriSema against tirzepatide at 5 mg.
This result marks a significant rebound for Novo Nordisk, which had earlier faced a setback when CagriSema fell short of Lilly's Zepbound on weight loss in a head-to-head obesity trial. CagriSema is widely seen as a successor to Wegovy, which faces patent expiries after 2030, making its competitive performance in this space strategically critical for the Danish drugmaker.
By the Numbers:
Why it matters: With the obesity and diabetes drug market intensely competitive, CagriSema's strong showing gives Novo Nordisk a credible next-generation contender. For clinicians and patients, it signals a potentially more effective treatment option on the horizon — one that addresses both weight and blood sugar control in a single weekly injection.
